Median OS and RMST at 12 and 24 months in the UK and USA by 1L drug class
| Analysis | Summary | US unweighted | US weighted* | UK |
| Overall | mOS (95% CI) | 10.4 (9.7 to 11.0) | 9.6 (9.0 to 10.2) | 9.5 (8.8 to 10.7) |
| 12 months RMST (SE) | 8.0 (0.07) | 7.8 (0.07) | 8.2 (0.13) | |
| 24 months RMST (SE) | 12.3 (0.15) | 11.9 (0.15) | 12.0 (0.27) | |
| Chemo | mOS (95% CI) | 8.1 (7.5 to 8.7) | 7.7 (7.1 to 8.3) | 8.1 (7.4 to 8.9) |
| 12 months RMST (SE) | 7.5 (0.09) | 7.4 (0.10) | 7.7 (0.16) | |
| 24 months RMST (SE) | 10.9 (0.18) | 10.6 (0.19) | 10.5 (0.3) | |
| IO mono. | mOS (95% CI) | 10.2 (8.5 to 11.6) | 13.9 (11.0 to 17.1) | 14.0 (10.7 to 20.6) |
| 12 months RMST (SE) | 7.6 (0.16) | 8.31 (0.17) | 8.79 (0.31) | |
| 24 months RMST (SE) | 12.3 (0.34) | 13.64 (0.36) | 14.23 (0.69) | |
| Targeted | mOS (95% CI) | 23.7 (22.4 to 27.1) | 21.6 (18.5 to 23.7) | 20.2 (16.0 to 30.5) |
| 12 months RMST (SE) | 10.1 (0.14) | 9.8 (0.15) | 9.8 (0.34) | |
| 24 months RMST (SE) | 17.3 (0.33) | 16.4 (0.35) | 16.3 (0.77) |
*US data standardised to reflect average characteristics of patients in the UK for age, sex, ECOG PS score (0–1 or 2+) and histology (squamous cell, non-squamous cell, unknown).
chemo, chemotherapy; ECOG PS, Eastern Cooperative Oncology Group Performance Status; IO mono, immunotherapy monotherapy; 1L, first line; mOS, median overall survival; OS, overall survival; RMST, restricted mean survival time.